Second-generation antipsychotic drugs have Second-generation antipsychotic drugs have been heralded as a significant advance in the been heralded as a significant advance in the treatment of patients with schizophrenia. treatment of patients with schizophrenia. However, except for clozapine, none has However, except for clozapine, none has been conclusively shown to be superior in been conclusively shown to be superior in resolving the symptoms of schizophrenia. resolving the symptoms of schizophrenia. Head-to-head studies are lacking. There is Head-to-head studies are lacking. There is little rational basis for selecting one over little rational basis for selecting one over another other than a patient's history of another other than a patient's history of response, lack of response or side-effects. response, lack of response or side-effects. The purpose of this study was to determine The purpose of this study was to determine if any of five second-generation antipsychoif any of five second-generation antipsychotics was more effective in treating acutely ill tics was more effective in treating acutely ill hospitalised patients with schizophrenia, hospitalised patients with schizophrenia, schizoaffective disorder or schizophrenischizoaffective disorder or schizophreniform disorder, and whether any of these form disorder, and whether any of these drugs had an advantage over haloperidol. drugs had an advantage over haloperidol. Two important features of this study were Two important features of this study were that it was designed to reflect clinical practhat it was designed to reflect clinical practice as a pragmatic clinical trial (March tice as a pragmatic clinical trial (March et et al al, 2005) and that it was not supported by , 2005) and that it was not supported by pharmaceutical companies. pharmaceutical companies.
METHOD METHOD Sample Sample
The study examined patients 18 years and The study examined patients 18 years and older of either gender, who were newly older of either gender, who were newly admitted to the hospital's psychiatric inadmitted to the hospital's psychiatric in- All patients in the study were diagnosed All patients in the study were diagnosed with schizophrenia, schizoaffective disorder with schizophrenia, schizoaffective disorder or schizophreniform disorder according to or schizophreniform disorder according to DSM-IV criteria (American Psychiatric DSM-IV criteria (American Psychiatric Association, 1994) . Patients with a history Association, 1994) . Patients with a history of substance misuse were included if the of substance misuse were included if the above diagnoses were present. Patients above diagnoses were present. Patients were included regardless of whether they were included regardless of whether they had recently taken antipsychotics before had recently taken antipsychotics before admission. Only patients who understood admission. Only patients who understood the nature of the study when it was fully the nature of the study when it was fully explained to them and who signed an explained to them and who signed an informed consent statement were included. informed consent statement were included. Institutional review board approval was Institutional review board approval was obtained for this study. obtained for this study.
Pregnant or lactating women and Pregnant or lactating women and patients with a medical condition in which patients with a medical condition in which pharmacotherapy would prove a significant pharmacotherapy would prove a significant clinical risk were excluded. Patients who clinical risk were excluded. Patients who had a clear history of response or lack had a clear history of response or lack of response to a particular antipsychotic of response to a particular antipsychotic drug and who, in the judgement of drug and who, in the judgement of the treating psychiatrist, would best be the treating psychiatrist, would best be treated accordingly, were not entered into treated accordingly, were not entered into the study. Patients with a diagnosis of the study. Patients with a diagnosis of bipolar disorder, major depressive disorder bipolar disorder, major depressive disorder or substance-induced psychotic disorder or substance-induced psychotic disorder were also excluded. were also excluded.
Study design Study design
Patients were admitted to one of the six Patients were admitted to one of the six general adult in-patient psychiatric units general adult in-patient psychiatric units based on bed availability, and this deterbased on bed availability, and this determined the treating psychiatrist. All units mined the treating psychiatrist. All units have the same number of patients and staffhave the same number of patients and staffing, and are indistinguishable with respect ing, and are indistinguishable with respect to diagnoses and acuity of patients. Newly to diagnoses and acuity of patients. Newly admitted patients with a diagnosis of admitted patients with a diagnosis of schizophrenia, schizoaffective disorder or schizophrenia, schizoaffective disorder or schizophreniform disorder were given inschizophreniform disorder were given information about the study and asked to formation about the study and asked to participate and provide informed consent. participate and provide informed consent.
Consenting patients were randomly Consenting patients were randomly assigned to treatment with one of six assigned to treatment with one of six antipsychotics: aripiprazole, haloperidol, antipsychotics: aripiprazole, haloperidol, olanzapine, quetiapine, risperidone and olanzapine, quetiapine, risperidone and ziprasidone. A randomised medication ziprasidone. A randomised medication assignment list was prepared before the assignment list was prepared before the study using the randomisation website study using the randomisation website http://www.randomization.com. Hospital http://www.randomization.com. Hospital staff with no clinical responsibilities and staff with no clinical responsibilities and no knowledge of the patients oversaw the no knowledge of the patients oversaw the assignment procedure and assigned medicaassignment procedure and assigned medications in sequential order, strictly following tions in sequential order, strictly following the randomised list. The treating psythe randomised list. The treating psychiatrist did not have access to this list. chiatrist did not have access to this list. Both the patient and the treating psyBoth the patient and the treating psychiatrist were aware of the antipsychotic chiatrist were aware of the antipsychotic being prescribed. The treating psychiatrists being prescribed. The treating psychiatrists followed standardised dosing guidelines followed standardised dosing guidelines based on the manufacturers' recommendabased on the manufacturers' recommendations, with the objective of obtaining a tions, with the objective of obtaining a maximum recommended dosage within maximum recommended dosage within 1-2 1-2 weeks. Patients were given at least weeks. Patients were given at least a 3-week a 3-week trial of the antipsychotic to detertrial of the antipsychotic to determine its effectiveness. As needed doses of mine its effectiveness. As needed doses of haloperidol, lorazepam and diphenhydrahaloperidol, lorazepam and diphenhydramine for agitation were permitted. Following mine for agitation were permitted. Following current practice at the facility, these medicacurrent practice at the facility, these medications are generally administered together and tions are generally administered together and intramuscularly for aggressive and threaintramuscularly for aggressive and threatening behaviour. Oral doses of diphenhytening behaviour. Oral doses of diphenhydramine were also administered, at the dramine were also administered, at the patient's request, for sleep. Benzatropine patient's request, for sleep. Benzatropine could also be prescribed for extrapyramidal could also be prescribed for extrapyramidal side-effects; it was the treating psychiaside-effects; it was the treating psychiatrist's decision whether to prescribe this trist's decision whether to prescribe this prophylactically or after side-effects develprophylactically or after side-effects developed. After the second week of treatment, oped. After the second week of treatment, an antidepressant, mood stabiliser or anxioan antidepressant, mood stabiliser or anxiolytic could be added at the psychiatrist's lytic could be added at the psychiatrist's discretion for significant mood symptoms discretion for significant mood symptoms or impulsivity. These medications are often or impulsivity. These medications are often considered essential in the acute treatment considered essential in the acute treatment of schizophrenia (McCue of schizophrenia (McCue et al et al, 2003) . , 2003) . If the treating psychiatrist assessed the If the treating psychiatrist assessed the patient to be improving on the medication, patient to be improving on the medication, it was continued until the patient was it was continued until the patient was well enough to be discharged. On the well enough to be discharged. On the other hand, if the patient showed no sigother hand, if the patient showed no significant improvement after at least 3 weeks nificant improvement after at least 3 weeks of treatment with the randomly assigned of treatment with the randomly assigned antipsychotic, the treating psychiatrist antipsychotic, the treating psychiatrist could discontinue the medication and the could discontinue the medication and the patient would be withdrawn from the patient would be withdrawn from the study. A period of 3 weeks was chosen study. A period of 3 weeks was chosen because treatment guidelines (American because treatment guidelines (American Psychiatric Association, 2004) have recomPsychiatric Association, 2004) have recommended waiting 2-4 weeks before changing mended waiting 2-4 weeks before changing antipsychotic pharmacotherapy, although antipsychotic pharmacotherapy, although there is evidence that the lack of improvethere is evidence that the lack of improvement in the first week or so of treatment ment in the first week or so of treatment predicts non-response (Correll predicts non-response (Correll et al et al, , 2003) . At any time, if the treating psy-2003). At any time, if the treating psychiatrist believed that continuing treatment chiatrist believed that continuing treatment with the selected antipsychotic would not with the selected antipsychotic would not be in the patient's best interest (e.g. signifibe in the patient's best interest (e.g. significant side-effects, medical instability and cant side-effects, medical instability and clinical deterioration), the medication was clinical deterioration), the medication was discontinued. discontinued.
Classification of outcome Classification of outcome
The antipsychotic was classified as effective The antipsychotic was classified as effective if the patient's mental status improved if the patient's mental status improved sufficiently to no longer necessitate acute sufficiently to no longer necessitate acute in-patient care. Such patients were either in-patient care. Such patients were either discharged to the community or moved to discharged to the community or moved to an alternative form of care. The antian alternative form of care. The antipsychotic was classified as ineffective if, in psychotic was classified as ineffective if, in the treating psychiatrist's assessment, the the treating psychiatrist's assessment, the patient had made no significant improvepatient had made no significant improvement after at least 3 weeks of treatment, ment after at least 3 weeks of treatment, and the drug was discontinued. If the mediand the drug was discontinued. If the medication was discontinued before the end of a cation was discontinued before the end of a 3-week trial owing to side-effects or signif-3-week trial owing to side-effects or significant deterioration in the patient's mental icant deterioration in the patient's mental state, it was also classified as ineffective. state, it was also classified as ineffective. The study site was a public hospital, with The study site was a public hospital, with the psychiatric in-patient service having the psychiatric in-patient service having minimal involvement with managed-care minimal involvement with managed-care health insurance plans; as a result, decisions health insurance plans; as a result, decisions about discharge were made solely on about discharge were made solely on clinical grounds and not influenced by clinical grounds and not influenced by insurance arrangements. insurance arrangements.
Data collection Data collection
The two main measures of effectiveness The two main measures of effectiveness used were the ability to discharge the used were the ability to discharge the patient from acute in-patient care and the patient from acute in-patient care and the total score on the Brief Psychiatric Rating total score on the Brief Psychiatric Rating Scale (BPRS; Overall & Gorham, 1988) . Scale (BPRS; Overall & Gorham, 1988) . Ratings were made at baseline, weekly up Ratings were made at baseline, weekly up to 3 weeks, and at end-point. The end-point to 3 weeks, and at end-point. The end-point was when the antipsychotic was determined was when the antipsychotic was determined to be effective or ineffective. to be effective or ineffective.
A clinician masked to the patient's anti-A clinician masked to the patient's antipsychotic regimen administered the BPRS. psychotic regimen administered the BPRS. Before the study began, this clinician had Before the study began, this clinician had 6 h of training per week for 2 months with 6 h of training per week for 2 months with the study's senior authors (R.E.M. and L.U.) the study's senior authors (R.E.M. and L.U.) in using the BPRS. At the end of the training in using the BPRS. At the end of the training period there was a sufficiently high correlaperiod there was a sufficiently high correlation of BPRS ratings. At the study's midtion of BPRS ratings. At the study's midpoint, a revalidation of the clinician's point, a revalidation of the clinician's BPRS ratings was performed with the BPRS ratings was performed with the study's senior authors (R.E.M. and L.U.). study's senior authors (R.E.M. and L.U.).
Side-effects were recorded concurrently Side-effects were recorded concurrently with BPRS ratings by a clinician masked with BPRS ratings by a clinician masked to the patient's antipsychotic regimen. to the patient's antipsychotic regimen. Side-effect data were elicited by sponSide-effect data were elicited by spontaneous report and clinical evaluation. A taneous report and clinical evaluation. A clinician masked to the patient's treatment clinician masked to the patient's treatment assessed Parkinsonian side-effects with the assessed Parkinsonian side-effects with the Simpson-Angus Scale (Simpson & Angus, Simpson-Angus Scale (Simpson & Angus, 1970) and akathisia with the Barnes 1970) and akathisia with the Barnes Akathisia Rating Scale (Barnes, 1989) . Akathisia Rating Scale (Barnes, 1989) .
Data analyses Data analyses
An An a priori a priori power analysis was performed power analysis was performed using G*POWER (Erdfelder using G*POWER (Erdfelder et al et al, 1996) . , 1996). For six experimental groups, an For six experimental groups, an a a of 0.05 of 0.05 and a postulated modest effect size of and a postulated modest effect size of 0.25, the study needed a total sample size 0.25, the study needed a total sample size of 324 to have a power (1 of 324 to have a power (17 7b b) of 0.95. ) of 0.95. Using these assumptions, the goal was to Using these assumptions, the goal was to have each treatment cell contain approxihave each treatment cell contain approximately 54 patients. The software StatView mately 54 patients. The software StatView version 5.0 (SAS Institute, Cary, North version 5.0 (SAS Institute, Cary, North Carolina, USA) was used for all other anaCarolina, USA) was used for all other analyses. The primary hypothesis was that the lyses. The primary hypothesis was that the six treatments would be differentially effecsix treatments would be differentially effective in treating acutely ill patients with tive in treating acutely ill patients with schizophrenia, schizoaffective disorder or schizophrenia, schizoaffective disorder or schizophreniform disorder. The effect of schizophreniform disorder. The effect of the antipsychotic on the main continuous the antipsychotic on the main continuous outcome variable (BPRS score) was anaoutcome variable (BPRS score) was analysed with analysis of variance evaluating lysed with analysis of variance evaluating change from baseline. Other continuous change from baseline. Other continuous variables were also examined with analyses variables were also examined with analyses of variance. Categorical variables were anaof variance. Categorical variables were analysed using a lysed using a w w 2 2 test. Logistic regression was test. Logistic regression was used to explore the effect of other indepenused to explore the effect of other independent variables on the categorical outcome dent variables on the categorical outcome variable. All initial analyses used a twovariable. All initial analyses used a twotailed tailed a a level of 0.05. level of 0.05.
RESULTS RESULTS
From January 2004 to February 2005 a From January 2004 to February 2005 a total of 584 admissions to the psychiatric total of 584 admissions to the psychiatric in-patient service with the diagnoses of in-patient service with the diagnoses of schizophrenia, schizoaffective disorder or schizophrenia, schizoaffective disorder or schizophreniform disorder were screened schizophreniform disorder were screened for entry into the study; 368 were ranfor entry into the study; 368 were randomised. This included some patients who domised. This included some patients who had previously participated in the study had previously participated in the study and who were rehospitalised during its and who were rehospitalised during its course and were randomised a second time course and were randomised a second time if they consented. For the purpose of this if they consented. For the purpose of this study, only the first randomised entry of study, only the first randomised entry of those entered more than once ( those entered more than once (n n¼41) was 41) was used for data analysis. Of the 327 patients used for data analysis. Of the 327 patients randomised, 8 were withdrawn from the randomised, 8 were withdrawn from the study for reasons unrelated to antipsychotic study for reasons unrelated to antipsychotic treatment and were not included in the data treatment and were not included in the data analysis. A total of 319 patients were analysis. A total of 319 patients were included in the analysis: of these, 301 had included in the analysis: of these, 301 had at least a 3-week trial of the antipsychotic at least a 3-week trial of the antipsychotic and in 18 cases participation was disand in 18 cases participation was discontinued because of side-effects or clinical continued because of side-effects or clinical deterioration ( Fig. 1) . deterioration ( Fig. 1 ). Table 1 shows the baseline characteristics Table 1 shows the baseline characteristics of the 319 patients whose data were used of the 319 patients whose data were used for analysis. No significant difference was for analysis. No significant difference was found among the six groups in BPRS total found among the six groups in BPRS total score, gender, diagnosis, length of illness score, gender, diagnosis, length of illness or comorbid substance misuse. There was or comorbid substance misuse. There was a significant difference in the age of particia significant difference in the age of participants among the six treatment groups: pants among the six treatment groups: post post hoc hoc analyses using Fisher's protected least analyses using Fisher's protected least significant difference (PLSD) test showed significant difference (PLSD) test showed that patients in the olanzapine group were that patients in the olanzapine group were significantly younger than patients in significantly younger than patients in the aripiprazole ( the aripiprazole (P P¼0.004), risperidone 0.004), risperidone ( (P P¼0.03) and quetiapine ( 0.03) and quetiapine (P P¼0.03) groups. 0.03) groups. In addition, patients given haloperidol were In addition, patients given haloperidol were significantly younger than those given aripisignificantly younger than those given aripiprazole ( prazole (P P¼0.03). As a result, age was 0.03). As a result, age was included in analyses as a covariable. included in analyses as a covariable.
Patient characteristics Patient characteristics

Treatment characteristics Treatment characteristics
The maximum daily dosage of antiThe maximum daily dosage of antipsychotic used in each treatment group psychotic used in each treatment group was as follows: aripiprazole, mean was as follows: aripiprazole, mean The use of additional medication The use of additional medication throughout the study is shown in Table 2 . throughout the study is shown in Table 2 . There was no significant overall difference There was no significant overall difference among the six treatment groups in the need among the six treatment groups in the need for haloperidol and lorazepam for for haloperidol and lorazepam for aggressive or agitated behaviour. The use aggressive or agitated behaviour. The use of diphenhydramine was significantly difof diphenhydramine was significantly different among the six groups, and there ferent among the six groups, and there was a significant medication was a significant medication6 6age interacage interaction effect ( tion effect (F F¼2.63, d.f.
2.63, d.f.¼5,307, 5,307, P P¼0.02). 0.02). Using Using post hoc post hoc analyses with Fisher's PLSD analyses with Fisher's PLSD test, patients treated with aripiprazole retest, patients treated with aripiprazole required significantly more diphenhydramine quired significantly more diphenhydramine than patients treated with olanzapine than patients treated with olanzapine 4 3 5 4 3 5 Progress of participants through the trial. There was a significant difference in the There was a significant difference in the use of benzatropine for extrapyramidal use of benzatropine for extrapyramidal side-effects (Table 2) ; significantly more side-effects (Table 2) ; significantly more patients treated with haloperidol or rispatients treated with haloperidol or risperidone were prescribed benzatropine, peridone were prescribed benzatropine, whereas no patient treated with aripiprawhereas no patient treated with aripiprazole or olanzapine was. For those patients zole or olanzapine was. For those patients taking this anticholinergic medication there taking this anticholinergic medication there was no significant difference in the mean was no significant difference in the mean daily dosage of benzatropine among the daily dosage of benzatropine among the treatments. treatments.
The six treatment groups did not differ The six treatment groups did not differ significantly in the addition of a mood stasignificantly in the addition of a mood stabiliser (divalproex 12 patients, gabapentin biliser (divalproex 12 patients, gabapentin 5 patients, lithium 2 patients, lamotrigine 5 patients, lithium 2 patients, lamotrigine 2 patients, oxcarbazepine 2 patients, 2 patients, oxcarbazepine 2 patients, carbamazepine 1 patient), antidepressant carbamazepine 1 patient), antidepressant (sertraline 3 patients, bupropion 1 patient, (sertraline 3 patients, bupropion 1 patient, escitalopram 1 patient, mirtazapine 1 escitalopram 1 patient, mirtazapine 1 patient, paroxetine 1 patient) or anxiolytic patient, paroxetine 1 patient) or anxiolytic (clonazepam 11 patients, lorazepam 5 (clonazepam 11 patients, lorazepam 5 patients, hydroxyzine 3 patients, buspirone patients, hydroxyzine 3 patients, buspirone 2 patients, diphenhydramine 2 patients, 2 patients, diphenhydramine 2 patients, alprazolam 1 patient) after the second week alprazolam 1 patient) after the second week of treatment. of treatment.
Clinical outcome Clinical outcome
Of 319 patients, 301 (94.4%) received Of 319 patients, 301 (94.4%) received at least a 3-week trial of the randomised at least a 3-week trial of the randomised antipsychotic. The antipsychotic was antipsychotic. The antipsychotic was prematurely discontinued in 18 patients prematurely discontinued in 18 patients (5.6%) -in 14 (4.4%) as a result of side-(5.6%) -in 14 (4.4%) as a result of sideeffects and in 4 (1.2%) because of a effects and in 4 (1.2%) because of a worsening of the patient's mental state. worsening of the patient's mental state. Table 3 shows the outcome of each Table 3 shows the outcome of each medication group. medication group.
There was an overall significant difThere was an overall significant difference in effectiveness among the six ference in effectiveness among the six antipsychotics, with haloperidol, olanzaantipsychotics, with haloperidol, olanzapine and risperidone being the most pine and risperidone being the most effective. To examine the influence of age effective. To examine the influence of age on the effectiveness of the antipsychotics, on the effectiveness of the antipsychotics, age was included with medication in a age was included with medication in a logistic regression of clinical outcome. Table 4 . Again, haloperidol, olangiven in Table 4 . Again, haloperidol, olanzapine and risperidone were significantly zapine and risperidone were significantly more effective than aripiprazole, quetiapine more effective than aripiprazole, quetiapine and ziprasidone, but not significantly better and ziprasidone, but not significantly better than each other. In addition, aripiprazole, than each other. In addition, aripiprazole, quetiapine and ziprasidone did not differ quetiapine and ziprasidone did not differ significantly from one another. There was significantly from one another. There was no significant difference among treatments no significant difference among treatments in the number of days until a patient's treatin the number of days until a patient's treatment was classified as effective. ment was classified as effective.
Improvement in the BPRS total score Improvement in the BPRS total score from baseline to study end-point did not from baseline to study end-point did not differ significantly among the six treatdiffer significantly among the six treatments. However, as a group, patients ments. However, as a group, patients taking haloperidol, olanzapine or risperitaking haloperidol, olanzapine or risperidone tended to have a greater decrease in done tended to have a greater decrease in BPRS total score (mean 15.6, s. 4. Psychotic medication added after the second week of antipsychotic treatment for significant mood symptoms or impulsivity. 4. Psychotic medication added after the second week of antipsychotic treatment for significant mood symptoms or impulsivity. 5. Benzatropine used on an ongoing basis for extrapyramidal side-effects. 5. Benzatropine used on an ongoing basis for extrapyramidal side-effects.
Side-effects Side-effects
The following side-effects caused 14
The following side-effects caused 14 patients to leave the trial: nausea, dizziness patients to leave the trial: nausea, dizziness and akathisia (aripiprazole); tremors, and akathisia (aripiprazole); tremors, Parkinsonism and akathisia (haloperidol); Parkinsonism and akathisia (haloperidol); anxiety and tachycardia (risperidone); and anxiety and tachycardia (risperidone); and rash, akathisia, dystonia and derealisation rash, akathisia, dystonia and derealisation (ziprasidone). The haloperidol and ziprasi-(ziprasidone). The haloperidol and ziprasidone groups had the most withdrawals done groups had the most withdrawals because of side-effects whereas the olanzabecause of side-effects whereas the olanzapine and quetiapine groups had none. The pine and quetiapine groups had none. The difference among the six treatments in rate difference among the six treatments in rate of withdrawals because of side-effects was of withdrawals because of side-effects was not statistically significant ( not statistically significant (w w 2 2 ¼9.15, 9.15, d.f. d.f.¼5, 5, P P¼0.10). 0.10). The proportion of patients reporting The proportion of patients reporting side-effects throughout the first 3 weeks side-effects throughout the first 3 weeks of the trial and at the end-point was of the trial and at the end-point was examined. After a week of treatment there examined. After a week of treatment there was a significant difference among treatwas a significant difference among treatments ( ments (w w 
DISCUSSION DISCUSSION
This study demonstrates differences in This study demonstrates differences in effectiveness among six antipsychotics in effectiveness among six antipsychotics in treating acutely ill hospitalised patients treating acutely ill hospitalised patients with schizophrenia, schizoaffective disorder with schizophrenia, schizoaffective disorder or schizophreniform disorder. Haloperidol, or schizophreniform disorder. Haloperidol, olanzapine and risperidone were more olanzapine and risperidone were more effective than aripiprazole, quetiapine and effective than aripiprazole, quetiapine and ziprasidone. These results were obtained ziprasidone. These results were obtained with minimum bias, using a randomised with minimum bias, using a randomised design, without support from the phardesign, without support from the pharmaceutical industry. The latter point is maceutical industry. The latter point is important as a study's findings must be important as a study's findings must be interpreted in light of the source of funding interpreted in light of the source of funding (Als-Nielsen (Als- Nielsen et al et al, 2003) . The definition of , 2003). The definition of effectiveness was a pragmatic one that mireffectiveness was a pragmatic one that mirrored clinical practice: an ill patient is rored clinical practice: an ill patient is admitted, treated and, when sufficiently admitted, treated and, when sufficiently improved, is discharged. In this study, an improved, is discharged. In this study, an effective antipsychotic improved a patient's effective antipsychotic improved a patient's psychosis enough so that he or she could be psychosis enough so that he or she could be 4 3 7 4 3 7 34 (64) 34 (64) 51 (89) 51 (89) 48 (92) 48 (92) 32 (64) 32 (64) 50 (88) 50 (88) 32 (64) 15 (28) 15 (28) 1 (2) 1 (2) 2 (4) 2 (4) 18 (36) 18 (36) 5 (9) 5 (9) 13 (26) 13 (26) Side-effects Side-effects 3 3 3 (6) 3 (6) 5 (9) 5 (9) (2001) also compared these two medications and found that these two medications and found that risperidone was more efficacious. Both of risperidone was more efficacious. Both of these studies were supported by pharmathese studies were supported by pharmaceutical companies. A third study (Ho ceutical companies. A third study (Ho et et al al, 1999) , without such support, found , 1999), without such support, found risperidone and olanzapine to be equally risperidone and olanzapine to be equally effective in the acute treatment of schizoeffective in the acute treatment of schizophrenia. Of these three studies, the first phrenia. Of these three studies, the first two dealt with efficacy (how a drug two dealt with efficacy (how a drug performs in controlled trials) and the third performs in controlled trials) and the third studied effectiveness (how a drug works in studied effectiveness (how a drug works in real-world populations). Effectiveness studies real-world populations). Effectiveness studies such as the one reported here may provide such as the one reported here may provide clinically useful information about pharmaclinically useful information about pharmacotherapy that is not obtainable from cotherapy that is not obtainable from studies of efficacy (Summerfelt & Meltzer, studies of efficacy (Summerfelt & Meltzer, 1998) . 1998).
Comparison with haloperidol Comparison with haloperidol
We chose haloperidol as a comparator We chose haloperidol as a comparator because of its proven efficacy in treating because of its proven efficacy in treating schizophrenia. Although there were more schizophrenia. Although there were more withdrawals because of side-effects with withdrawals because of side-effects with this drug, those who were able to tolerate this drug, those who were able to tolerate it had a response rate of 98%. Trials it had a response rate of 98%. Trials that have examined efficacy of the secondthat have examined efficacy of the secondgeneration antipsychotics used in this study generation antipsychotics used in this study (Marder & Meibach, 1994; Beasley (Marder & Meibach, 1994; Beasley et al et al, , 1996; Arvanitis & Miller, 1997; Carnahan 1996; Arvanitis & Miller, 1997; Carnahan et al et al, 2001; Kane , 2001; Kane et al et al, 2002) reported that , 2002) reported that these drugs were equal to first-generation these drugs were equal to first-generation antipsychotics such as haloperidol. antipsychotics such as haloperidol. Subsequent meta-analyses that have comSubsequent meta-analyses that have compared efficacy between second-generation pared efficacy between second-generation antipsychotics and haloperidol have been antipsychotics and haloperidol have been inconclusive. Leucht inconclusive. Leucht et al et al (1999) found (1999) found a slight advantage of risperidone and a slight advantage of risperidone and olanzapine over haloperidol for efficacy, olanzapine over haloperidol for efficacy, and a larger advantage of risperidone, and a larger advantage of risperidone, olanzapine and quetiapine over haloperidol olanzapine and quetiapine over haloperidol for extrapyramidal side-effects. The metafor extrapyramidal side-effects. The metaanalysis by Davis analysis by Davis et al et al (2003) found (2003) found risperidone and olanzapine to be more risperidone and olanzapine to be more efficacious than first-generation antipsyefficacious than first-generation antipsychotics, including haloperidol. Geddes chotics, including haloperidol. Geddes et al et al (2000) found no advantage of the second- (2000) found no advantage of the secondgeneration antipsychotics over haloperidol generation antipsychotics over haloperidol for either efficacy or side-effects when an for either efficacy or side-effects when an optimal dosage of haloperidol of 6-12 mg optimal dosage of haloperidol of 6-12 mg per day was used. The mean daily dosage per day was used. The mean daily dosage of 16 mg in our study was higher than this. of 16 mg in our study was higher than this. Perhaps if lower dosages had been used in Perhaps if lower dosages had been used in conjunction with prophylactic anticholinerconjunction with prophylactic anticholinergic medication, side-effects would have gic medication, side-effects would have been less of a problem. The use of halobeen less of a problem. The use of haloperidol as an effective and inexpensive peridol as an effective and inexpensive treatment, even compared with olanzapine treatment, even compared with olanzapine and risperidone, has had additional support and risperidone, has had additional support 
Concomitant psychotropic Concomitant psychotropic medication medication
The use of as needed medication, including The use of as needed medication, including haloperidol, during the study period was an haloperidol, during the study period was an unavoidable complicating factor. For safety unavoidable complicating factor. For safety reasons it was necessary for the staff to reasons it was necessary for the staff to have at their disposal the conventional have at their disposal the conventional treatments used for emergency situations. treatments used for emergency situations.
Although not to a degree of statistical Although not to a degree of statistical significance, patients treated with aripiprasignificance, patients treated with aripiprazole, quetiapine and ziprasidone required zole, quetiapine and ziprasidone required more haloperidol and lorazepam than more haloperidol and lorazepam than patients in the other three medication patients in the other three medication groups. However, this extra use of groups. However, this extra use of haloperidol, one of the more effective antihaloperidol, one of the more effective antipsychotics in this trial, would probably have psychotics in this trial, would probably have had a positive effect on the clinical outcome had a positive effect on the clinical outcome of patients treated with it. The as needed use of patients treated with it. The as needed use of halo of haloperidol might also have obscured a peridol might also have obscured a difference difference in its effectiveness as the primary in its effectiveness as the primary antipsychotic and the other two more antipsychotic and the other two more effective drugs, olanzapine and risperidone. effective drugs, olanzapine and risperidone.
Younger patients prescribed aripipraYounger patients prescribed aripiprazole required significantly more diphenzole required significantly more diphenhydramine compared with younger patients hydramine compared with younger patients taking other medications. An interpretation taking other medications. An interpretation is that aripiprazole was much more activatis that aripiprazole was much more activating in younger patients. However, diphening in younger patients. However, diphenhydramine is usually administered with hydramine is usually administered with haloperidol and lorazepam when as needed haloperidol and lorazepam when as needed medication is used at the facility. It is also medication is used at the facility. It is also possible that younger patients taking aripossible that younger patients taking aripiprazole required diphenhydramine more piprazole required diphenhydramine more often for sleep. At this point, firm concluoften for sleep. At this point, firm conclusions cannot be drawn from this finding. sions cannot be drawn from this finding.
Side-effects Side-effects
More patients taking haloperidol and zipraMore patients taking haloperidol and ziprasidone left the study because of side-effects, sidone left the study because of side-effects, whereas no one taking olanzapine or quetiawhereas no one taking olanzapine or quetiapine did so. Patients in all six medication pine did so. Patients in all six medication groups reported having side-effects about groups reported having side-effects about one-third or more of the time. Patients takone-third or more of the time. Patients taking haloperidol and ziprasidone had more ing haloperidol and ziprasidone had more complaints at the beginning, but at endcomplaints at the beginning, but at endpoint the distribution of side-effects was point the distribution of side-effects was fairly even among the six treatments. fairly even among the six treatments. Except for those elicited by rating scales, Except for those elicited by rating scales, side-effects were obtained from the side-effects were obtained from the patient's report. The validity of these patient's report. The validity of these reported side-effects is open to question, as reported side-effects is open to question, as patients were often taking other medicapatients were often taking other medications or had physical symptoms possibly tions or had physical symptoms possibly unrelated to antipsychotic treatment. Howunrelated to antipsychotic treatment. However, these reported side-effects are relevant: ever, these reported side-effects are relevant: the patient's perception that they were the patient's perception that they were caused by the antipsychotic would certainly caused by the antipsychotic would certainly affect the individual's present comfort and affect the individual's present comfort and future adherence to the drug regime. future adherence to the drug regime.
Patients given aripiprazole or olanzapine Patients given aripiprazole or olanzapine required no concomitant anticholinergic required no concomitant anticholinergic medication, whereas a small percentage of medication, whereas a small percentage of patients on quetiapine or ziprasidone and patients on quetiapine or ziprasidone and a significant minority of patients on haloa significant minority of patients on haloperidol or risperidone did need it. These reperidol or risperidone did need it. These results are consistent with each drug's sults are consistent with each drug's reported propensity to cause extrapyramireported propensity to cause extrapyramidal side-effects. No significant change was dal side-effects. No significant change was found among treatments in ratings of found among treatments in ratings of parkinsonism and akathisia using the parkinsonism and akathisia using the Simpson-Angus Scale and the Barnes Simpson-Angus Scale and the Barnes Akathisia Rating Scale. An interpretation Akathisia Rating Scale. An interpretation of this result is that extrapyramidal sideof this result is that extrapyramidal sideeffects were not a problem for the majority effects were not a problem for the majority of patients in this study and were resolved of patients in this study and were resolved with anticholinergic medication if present. with anticholinergic medication if present. An exception is a small number of patients An exception is a small number of patients taking haloperidol who had significant protaking haloperidol who had significant problems with these side-effects. As fewer than blems with these side-effects. As fewer than half of the patients given haloperidol were half of the patients given haloperidol were also given anticholinergic medication, a also given anticholinergic medication, a more consistent use of it prophylactically more consistent use of it prophylactically might have prevented extrapyramidal sidemight have prevented extrapyramidal sideeffects. Owing to the relatively short effects. Owing to the relatively short treatment period of this study, the treatment period of this study, the important side-effects of weight gain, important side-effects of weight gain, hyperglycaemia, lipid abnormalities and hyperglycaemia, lipid abnormalities and tardive dyskinesia were not evaluated. tardive dyskinesia were not evaluated.
Study limitations Study limitations
Qualifying any conclusion about effectiveQualifying any conclusion about effectiveness is the lack of differentiation among ness is the lack of differentiation among the antipsychotics with respect to the BPRS the antipsychotics with respect to the BPRS total score. As there was a significant differtotal score. As there was a significant difference in this variable between effectively and ence in this variable between effectively and ineffectively treated patients, the BPRS ineffectively treated patients, the BPRS total score did have validity as an indicator total score did have validity as an indicator of clinical improvement. As a group, the of clinical improvement. As a group, the more effective antipsychotics were assomore effective antipsychotics were associated with a greater mean change in BPRS ciated with a greater mean change in BPRS total score than the less effective ones, total score than the less effective ones, although not to a statistically significant although not to a statistically significant degree. A likely possibility is that our study degree. A likely possibility is that our study might not have had sufficient power to might not have had sufficient power to detect differences among the six treatments. detect differences among the six treatments. A A post hoc post hoc power analysis of this comparipower analysis of this comparison showed a power of 0.39. There might son showed a power of 0.39. There might also have been aspects of the patient's clinalso have been aspects of the patient's clinical condition relating to discharge that ical condition relating to discharge that were not reflected in the BPRS total score; were not reflected in the BPRS total score; for example, haloperidol, olanzapine and for example, haloperidol, olanzapine and risperidone might have been more successrisperidone might have been more successful at controlling disturbed behaviour and ful at controlling disturbed behaviour and as a result patients treated with these would as a result patients treated with these would have been more readily discharged. Howhave been more readily discharged. However, if sedation alone accounted for the ever, if sedation alone accounted for the results then quetiapine -one of the most results then quetiapine -one of the most sedating of the six antipsychotics -would sedating of the six antipsychotics -would have had an advantage. In addition, no difhave had an advantage. In addition, no difference was found among the medications ference was found among the medications in changes in the BPRS factors, including in changes in the BPRS factors, including hostility and activation. Although the defihostility and activation. Although the definition of effectiveness used in this study nition of effectiveness used in this study may be a reflection of improvement in only may be a reflection of improvement in only some of the clinical manifestations of some of the clinical manifestations of schizophrenia, improving the condition of schizophrenia, improving the condition of patients so that they can be discharged patients so that they can be discharged sooner remains a clinically important sooner remains a clinically important objective. objective.
The presence of a statistically sigThe presence of a statistically significant -although not clearly clinically nificant -although not clearly clinically significant -difference in age among significant -difference in age among the treatment groups may indicate that the treatment groups may indicate that there was unsuccessful randomisation. The there was unsuccessful randomisation. The patients were assigned treatment from a list patients were assigned treatment from a list prepared before the study began and by prepared before the study began and by someone who had no knowledge of the someone who had no knowledge of the patients, including their age, so it is unlikely patients, including their age, so it is unlikely that this represented an intentional bias. that this represented an intentional bias. Although the differences in age cannot be Although the differences in age cannot be explained, age was not a significant factor explained, age was not a significant factor in determining effectiveness. in determining effectiveness.
A major weakness of this study is its A major weakness of this study is its questionable generalisability. The results, questionable generalisability. The results, although robust, may reflect idiosyncrasies although robust, may reflect idiosyncrasies of clinical practice by the psychiatric inof clinical practice by the psychiatric inpatient service at our facility. Also, the patient service at our facility. Also, the definition of effectiveness was relevant to definition of effectiveness was relevant to hospitalised patients. The effectiveness of hospitalised patients. The effectiveness of these medications in out-patients might be these medications in out-patients might be different. By American guidelines, a 3-week different. By American guidelines, a 3-week minimum trial would be sufficient to minimum trial would be sufficient to determine an antipsychotic's effectiveness; determine an antipsychotic's effectiveness; however, this might be considered too short however, this might be considered too short for European psychiatric practice, where a for European psychiatric practice, where a minimum of 6 weeks is needed (National minimum of 6 weeks is needed (National Institute for Clinical Excellence, 2002) . Institute for Clinical Excellence, 2002) . Since all of the antipsychotics were effective Since all of the antipsychotics were effective for the majority of the patients by the for the majority of the patients by the criteria used in this study, the marginal bencriteria used in this study, the marginal benefit of a longer trial would probably be efit of a longer trial would probably be minimal. minimal.
A psychiatrist who was not masked to A psychiatrist who was not masked to the antipsychotic being used made the decithe antipsychotic being used made the decision that a patient no longer needed acute sion that a patient no longer needed acute in-patient care, a major outcome variable. in-patient care, a major outcome variable. However, this decision was not made by However, this decision was not made by the treating psychiatrist in isolation and the treating psychiatrist in isolation and was the product of input from the patient, was the product of input from the patient, the patient's family and other members of the patient's family and other members of the treatment team. During the study perithe treatment team. During the study period there was no significant difference in od there was no significant difference in the length of stay of patients of the 14 psythe length of stay of patients of the 14 psychiatrists who participated in the study chiatrists who participated in the study ( (F F¼1.50, d.f.
1.50, d.f.¼13,164, 13,164, P P¼0.12). There is 0.12). There is also the possibility that, as a result of bias, also the possibility that, as a result of bias, the psychiatrists waited longer with some the psychiatrists waited longer with some of the drugs before classifying them as inof the drugs before classifying them as ineffective, thereby increasing the chance of effective, thereby increasing the chance of a favourable outcome. However, in addia favourable outcome. However, in addition to there being no difference in the time tion to there being no difference in the time needed for a drug to be effective, there was needed for a drug to be effective, there was no significant difference in the number of no significant difference in the number of days until a treatment was classified as inefdays until a treatment was classified as ineffective ( fective (F F¼0.82, d.f. 0.82, d.f.¼5,48, 5,48, P P¼0.54 ). An-0.54). Another limitation of the study is that other limitation of the study is that although standard recommended dosages although standard recommended dosages were used, optimal therapeutic dosing for were used, optimal therapeutic dosing for the newer second-generation antipsychotics the newer second-generation antipsychotics is still uncertain. As aripiprazole, quetiais still uncertain. As aripiprazole, quetiapine and ziprasidone are further studied, pine and ziprasidone are further studied, perhaps the recommended therapeutic doperhaps the recommended therapeutic dosages of these drugs will be revised and, sages of these drugs will be revised and, hence, their effectiveness. hence, their effectiveness.
Clinical implications Clinical implications
Based on these findings, haloperidol, risperBased on these findings, haloperidol, risperidone and olanzapine are more effective idone and olanzapine are more effective antipsychotics for the acute treatment of antipsychotics for the acute treatment of hospitalised patients with schizophrenia, hospitalised patients with schizophrenia, schizoaffective disorder or schizophrenischizoaffective disorder or schizophreniform disorder. These drugs are reasonable form disorder. These drugs are reasonable first choices unless the patient's history first choices unless the patient's history suggests otherwise. Haloperidol, risperisuggests otherwise. Haloperidol, risperidone and olanzapine are also more potent done and olanzapine are also more potent antagonists of dopamine-2 receptors than antagonists of dopamine-2 receptors than the other three antipsychotics tested, which the other three antipsychotics tested, which may account for their superior effectiveness may account for their superior effectiveness (Kapur (Kapur et al et al, 2000) . Olanzapine and risper-, 2000) . Olanzapine and risperidone were better tolerated in the short idone were better tolerated in the short term than haloperidol; however, greater term than haloperidol; however, greater use of anticholinergic medication with use of anticholinergic medication with haloperidol would probably have improved haloperidol would probably have improved its tolerability. This study did not address its tolerability. This study did not address long-term effectiveness and side-effects. long-term effectiveness and side-effects. The number of patients with schizophrenia, The number of patients with schizophrenia, schizoaffective disorder and schizophrenischizoaffective disorder and schizophreniform disorder who require acute treatment form disorder who require acute treatment is substantial and more studies with is substantial and more studies with minimal bias are greatly needed to assist minimal bias are greatly needed to assist clinicians in making thoughtful treatment clinicians in making thoughtful treatment decisions. decisions. 
